every F'ing time someone starts talking about new highs, every time. should have known to get out when I saw the comment
1
11
Report
Nyx
:
Don't know about new highs but I guarantee if I bought the stock it's going to fall for over a week straight. This is the 5th time already my business sense is . Bought at 2.55 I'll just take the loss.
Johnny Mnemonic
OP
Nyx
:
Ive been on a 4 month rise, with no bad calls. if this doesn't come up, it'll be my first bad call in awhile. I'm in at 2.10. the short float has been over 30% for almost a week, so I'm gonna hold and see what happens. it has the potential for a 50% rise at least
Johnny Mnemonic
OP
Nyx
:
lol, I go through ups and downs, but I've been making allot of good calls lately for almost 4 months, glad to see this is finally going up. I was in UAVS at 1.55(sold at 8.75), KWE at .60(sold at 1.40). those are my latest big ones. I'm expecting KITT to take off at some point, looking for a government contract, in at .90
$CervoMed (CRVO.US)$ CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies Tuesday, 10th December at 7:00 am —Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks— —Favorable safety and tolerability results with no new safety signal identified— —Target plasma drug concentrations not achieved during 16-week double-blind phase of the trial— —Trial participants ...
CervoMed Stock Forum
should have known to get out when I saw the comment
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
Tuesday, 10th December at 7:00 am
—Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks—
—Favorable safety and tolerability results with no new safety signal identified—
—Target plasma drug concentrations not achieved during 16-week double-blind phase of the trial—
—Trial participants ...
No comment yet